Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616306 | 0.95 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9AHPGDNPC1ALDH1A1 | |
| SCHEMBL15969027 | 0.84 | MEN1 (0.63) | HPGDLMNATHRATHRBFFAR4 | |
| SCHEMBL6811950 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2RAB9AHPGDNPC1ALDH1A1 | |
| SCHEMBL19124684 | 0.82 | LMNA (0.74) | SMN1; SMN2RAB9AHPGDNPC1ALDH1A1 | |
| SCHEMBL25922476 | 0.82 | GLRA1 (0.63) | SMN1; SMN2RAB9AHPGDNPC1ALDH1A1 | |
| SCHEMBL8843690 | 0.81 | SMN1; SMN2 (0.73) | SMN1; SMN2RAB9AHPGDNPC1ALDH1A1 | |
| SCHEMBL10770964 | 0.80 | MEN1 (0.71) | SMN1; SMN2RAB9AHPGDNPC1ALDH1A1 | |
| SCHEMBL7809050 | 0.80 | KMT2A (0.57) | SMN1; SMN2RAB9AHPGDNPC1ALDH1A1 | |
| SCHEMBL13064649 | 0.79 | TSHR (0.43) | SMN1; SMN2HPGDALDH1A1MAPTGAA | |
| SCHEMBL3813157 | 0.79 | GLRA1 (0.50) | SMN1; SMN2HPGDLMNAGLRA1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718617-B1 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| US-20090149463-A1 | Therapeutic agents | CHENG LEIFENG | 2009-06-11 | — | — | US | disclosed |
| EP-0828513-B1 | COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS | PFIZER (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-0777652-B1 | NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES | PFIZER (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6258827-B1 | HYDROXYAROMATIC HETEROCYCLIC ALKANOLS AND LEVODOPA | PFIZER INC. | 2001-07-10 | — | — | US | disclosed |
| US-6046213-A | Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives | PFIZER INC. (US) | 2000-04-04 | — | — | US | disclosed |
| EP-0828513-A2 | COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS | PFIZER INC. (US) | 1998-03-18 | — | — | EP | disclosed |
| EP-0777652-A1 | NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES | PFIZER INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996037226-A2 | COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS | PFIZER INC. (US) | 1996-11-28 | — | — | WO | disclosed |
| WO-1996006081-A1 | NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES | PFIZER INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149463-A1 | Therapeutic agents | NLN, BDNF, GAP43 | SMN1; SMN2 168/4885RAB9A 1816/4885HPGD 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.